Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/12—Aerosols; Foams
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4704—2-Quinolinones, e.g. carbostyril
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/16—Central respiratory analeptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Definitions

• the present invention relates to a pharmaceutical formulation for use in the administration of a long-acting ⁇ 2 -agonist by inhalation.
• Asthma is a disease which is becoming more prevalent and is the most common disease of childhood. It can be identified by recurrent wheeze and intermittent air flow limitation. Despite many advances in its understanding, said pathology remains a poorly understood and often poorly treated disease.
• COPD chronic obstructive pulmonary disease
• COPD chronic obstructive pulmonary disease
• Chronic bronchitis is characterized by excessive secretion of bronchial mucus, whereas emphysema denotes abnormal, permanent enlargement of air spaces distal to the terminal bronchiole, with destruction of their walls and without obvious fibrosis (American Toracic Society). Each condition is treated as specific diseases.
• Chronic obstructive bronchiolitis is due to obstruction of the peripheral airways as a result of inflammation in the bronchioles.
• ⁇ 2 -Adrenoceptor agonists have been the mainstay of treatment for asthma for many years in view of their prompt bronchodilation effects. Previous researches have also shown that ⁇ 2 -agonists have potent anti- inflammatory capabilities, e.g. represented by suppression of release of the pro-inflammatory cytokines.
• the first generation drugs such as salbutamol or fenoterol were characterized by a relatively short duration of action which has been considered as a disadvantage particularly for patients with nocturnal asthma. Moreover, they have limited effects in COPD, since this disease involves 'irreversible' airways obstruction. The development of longer acting ⁇ 2 -agonists such as formoterol, salmeterol and TA 2005 has therefore been heralded as a major new development in the treatment of asthma.
• ⁇ 2 -agonists may have acute ant inflammatory activity in vivo (Johnson M Clin Exp Allergy 1992, 22, 177- 181; Stelmach I et al Ann Allergy Asthma Immunol 2002, 89, 67-73). These drugs are a new interesting therapeutic option for patients with chronic obstructive pulmonary disease (COPD) as well since they have been shown to significantly improve lung function and symptom control.
• COPD chronic obstructive pulmonary disease
• ⁇ 2 -Adrenergic agonists can also stimulate alveolar fluid clearance in several animal species and in ex vivo rat and human lungs.
• beta-adrenergic agonist therapy has been proposed as a possible treatment for accelerating the resolution of pulmonary oedema in patients with acute pulmonary oedema (Sacuma T et al Am J Respir Crit Care Med 1997, 155, 506-512). Treatment with ⁇ 2 -agonists may also increase the secretion of surfactant and perhaps exert an anti-inflammatory effect, thus helping to restore vascular permeability of the lung (Ware L et al New Eng. J Med 2000, 342, 1334-1349.
• Drugs intended for the treatment of lung diseases such as asthma and COPD are currently administered by pulmonary delivery which relies on inhalation of an aerosol through the mouth and throat so that the drug substance can reach the lung. They can be administered as aqueous or hydro alcoholic formulations through a nebuliser, as dry powders by means of Dry Powder Inhalers or in halogenated hydrocarbon propellants.
• the propellant-based systems require suitable pressurized metered-dose inhalers (pMDIs) which release a metered dose of medicine upon each actuation.
• the relevant formulations can be in the form of solutions or suspensions. Solution formulations, with respect to suspensions, do not present problems of physical stability of the suspended particles and so could guarantee a higher dose uniformity and reproducibility.
• hydrofluoroalkanes (HFAs) known also as hydro-fluoro-carbons (HFCs)] would be mandatory propellants as chlorofluorocarbons (known also as Freons or CFCs), which were for many years the preferred propellants aerosols for pharmaceutical use, have been implicated in the destruction of the ozone layer so their use is being phased out.
• HFA 134a 1,1,1,2-tetrafluoroethane
• HFA 227) 1,1,1,2,3,3,3-heptafluoropropane
• the aerodynamic size distribution of the inhaled particles is the most important variable in defining the site of droplet or particle deposition in the lungs of the patient; in short, it will determine whether drug targeting succeeds or fails. See P. Byron, "Aerosol Formulation, Generation, and Delivery Using Nonmetered Systems, “Respiratory Drug Delivery, 144-151,144 (CRC Press, 1989).
• a prerequisite in developing a therapeutic aerosol is a preferential particle size.
• the particle size of the cloud is dominated by the particle size of the suspended drug, defined by the milling/mi cronization process.
• the volumetric contribution of suspended drug particles is absent and much finer liquid droplets clouds, largely defined by the drug concentration in the solution, are generated.
• Solid particles and/or droplets in an aerosol formulation can be characterized by their mass median aerodynamic diameter (MMAD, the diameter around which the mass aerodynamic diameters are distributed equally).
• MMAD mass median aerodynamic diameter
• Particle deposition in the lung depends largely upon three physical mechanisms: i) impaction, a function of particle inertia; ii) sedimentation due to gravity; and iii) diffusion resulting from Brownian motion of fine, submicrometer
• particles should preferentially deposit in the upper-to mid-pulmonary region (bronchiole region), so they should have a MMAD of about 1.5(2.0) to about 5.0 microns, preferably approximately 3 microns (Zanen P et al Int J Pharm 1994, 107, 211-217; Int J Pharm 1995, 114, 111- 115; Thorax, 1996, 51, 977-980).
• particles having aerodynamic diameters of greater than about 5 microns generally do not reach the lung since they tend to impact the back of the throat and are swallowed and possibly orally absorbed, while particles smaller than 1.5 (2.0) micron, i.e., about 0.5 to about 2 microns, capable of reaching the alveolar region, have been considered undesirable because they can be absorbed into the bloodstream and might enhance the undesired systemic effects of the drugs.
• Particles having diameters smaller than about 0.5 microns have been generally considered as not therapeutically useful as they can be exhaled.
• pMDI formulations of ⁇ 2 -agonist have traditionally been formulations able to deliver particles whose larger fraction is comprised between 2 and 5 microns and the amount of those below 1 micron is very limited since the former are small enough to reach the upper-to mid- pulmonary region, but are too large to reach the alveoli.
• Formoterol ⁇ (R,R)-( ⁇ )-N-[2-hydroxy-5-[l-hydroxy-2-[[2-(4-methoxy- phenyl)-l-methylethyl]amino]ethyl]-phenyl]formamide ⁇ is a selective ⁇ 2 - receptor agonist, exerting, upon inhalation, a prolonged bronchodilation up to 12 hours. It is currently marketed as CFC formulation (Foradil ® ).
• the object of the present invention is to provide a pharmaceutical aerosol solution formulation to be administered by pMDI, having a suitable shelf-life for pharmaceutical use, comprising formoterol as active ingredient, a HFA propellant and a suitable amount of co-solvent wherein the active ingredient is completely dissolved in the propellant-cosolvent system and the amount of residual water is less than 1500 ppm on the total weight of the formulation.
• Said solution is able of providing on actuation of the formulation a fraction of particles equal or less than 1.1 micron of at least 30% as defined by the content stages S6-AF of an Andersen Cascade Impactor relative to the total amount of the fine particle dose collected in the stages S3-AF of the impactor.
• the formulation of the invention is able to deliver a significant fraction of particles having a diameter equal or less than 1.1 micron, comprising both extrafine particles, according to the definition of Martin R in J Allergy Clin Immunol 2002, 109 (Suppl 2), 447-460 and particles having a diameter equal or less than 0.3 micron (ultrafine particles, according to the definition of other authors).
• the formulation of the invention will be hereinafter referred to as superfine formulation.
• a pharmaceutical aerosol formulation comprising 0.003-0.192% w/v formoterol or one of its pharmaceutically acceptable salt such as fumarate as active ingredient in solution in a liquefied HFA propellant and a co-solvent preferably selected from a pharmaceutically acceptable alcohol, characterized in that the fraction of particles equal or less than 1.1 micron is higher or of at least 30% and the content of humidity as determined by Karl-Fischer method is less than 1500 ppm.
• the pH of the formulation is to between 2.5 and 5.0 as determined in the model vehicle system reported in EP 1157689.
• WO 98/34596 in the name of 3 M refers to solution formulations containing a propellant and a physiologically acceptable polymer which could help the solubilisation and the stability as well of the active ingredients.
• WO 98/34595 in the name of Jago Research refers to aerosol formulations in the form of solutions or suspensions in which the propellant is a mixture of a HFA and carbon dioxide.
• the presence of carbon dioxide can improve either physical and chemical stability of active compounds.
• Formoterol is cited among the active compounds which can be used but no examples are reported.
• WO 00/06121 in the name of Jago Research refers to propellant mixtures for aerosol containing dinitrogen monoxide and a hydrofluoroalkane in the preparation of suspension and solution aerosols.
• the use of dinitrogen monoxide may improve the stability at storage of oxidation-sensitive active ingredients.
• LABAs such as formoterol fumarate and salmeterol xinafoate, only examples referred to suspensions are reported.
• WO 99/65460 in the name of Baker Norton claims pressurised MDI's containing stable formulations of a ⁇ 2 -agonist drug in suspension or solution.
• Examples refer to solutions of formoterol fumarate containing an HFA propellant and ethanol as a co-solvent, filled in conventional aluminium or plastic coated glass cans. Samples stored under accelerated conditions (40°C, 15% relative humidity) for a very short period, one month, exhibited about 10% loss of drug. According to the pharmaceutical guideline ICH Q1A "Stability Testing of new Active Substances (and Medicinal Products)" of October 1993, a 5% change in assay of the active ingredient from its initial value does not meet the criteria of acceptance. Moreover, even said document is silent about the dramatic effect of residual water on the chemical stability of formoterol and its salts.
• WO 98/56349 the applicant described solution compositions for use in an aerosol inhaler, comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a co-solvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
• HFA hydrofluoroalkane
• MMAD mass median aerodynamic diameter
• a small quantity of water may be added to the composition to improve the solution of the active material and/or the low volatility component in the cosolvent.
• the applicant disclosed aerosol pharmaceutical compositions comprising a ⁇ 2 -agonist belonging to the class of phenylalkylamino derivatives in solution in a HFA propellant, a co-solvent whose apparent pH has been adjusted to between 2.5 and 5.0 in order to guarantee an adequate shelf-life.
• isopropyl myristate (IPM) as a low-volatility is added in order to either increase the MMAD of the aerosol particles and further improving the stability of the formulation.
• IPM isopropyl myristate
• Formoterol- based HFA 134a solution formulations containing 12% w/w ethanol with or without 1.0% w/w IPM are reported in example 5.
• the formulations of the invention can also comprise a further active ingredient.
• the addition of a corticosteroid to a long-acting ⁇ 2 -agonist gives optimal control of asthma in most patients and relevant fixed combinations are increasingly used as a convenient controller in patients with persistent asthma.
• Another object of the present invention is to provide highly efficient formoterol formulations further comprising a steroid.
• the high fraction of superfine particles of the formulation of the invention can allow both drugs to reach the small peripheral airways region in such a way as to better exercise their synergic effects in distal lung diseases (vide supra).
• a further aspect of the present invention is to provide highly efficient formoterol formulations in combination with an anticholinergic atropine-like derivative such as ipratropium bromide, oxitropium bromide and tiotropium bromide in order to provide a medicament particularly effective for the treatment of COPD.
• an anticholinergic atropine-like derivative such as ipratropium bromide, oxitropium bromide and tiotropium bromide
• a still further aspect of the invention comprises the use of the formoterol fully dissolved in the propellant / co-solvent system and capable of providing on actuation a fraction of at least 30% of emitted particles with an aerodynamic diameter equal or less than 1.1 microns, for the treatment of respiratory disorders such as asthma and COPD.
• the formulation of the invention can be particularly effective for the treatment of asthma, COPD and, generally, of airway obstruction conditions wherein the pathology is associated with mucus hypersecretion which hinders the diffusion of the drug.
• ALI acute lung injury
• ARDS acute respiratory distress syndrome
• the aerosol formulations of the invention comprise an HFA propellant and a co-solvent wherein the active ingredient is fully dissolved in such a way that the formulations are able of providing on actuation a fraction of emitted particles of equal or less than 1.1 microns higher or equal to 30% as defined by the content stages S6-AF of an Andersen Cascade Impactor relative to the total fine particle dose collected in the stages S3-AF of the impactor, advantageously higher than 40%, preferably higher than 50%, more preferably higher than 60%, even more preferably higher than 70%.
• the formulations of the invention are free of other excipients such as surfactants besides the solubilisation agent and the propellant.
• HFA propellants examples include 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane (HFA227) and mixtures thereof.
• the preferred propellant is 1,1,1,2-tetrafluoroethane (HFA134a).
• An alternative propellant of interest is 1,1,1,2,3,3,3-heptafluoro-n-propane (HFA227).
• the co-solvent is selected from the group of lower alkyl (C ⁇ -C 4 ) alcohols, polyols, polyalkylene glycols and their combinations.
• suitable co-solvents are (poly)alkoxy derivatives including polyalkoxy alcohols, [such as 2 ⁇ (2-ethoxyethoxy) ethanol available under the trademark Transcutol ® ].
• the co-solvent is an alcohol.
• the preferred one is ethanol. Since the presence of water has to be avoided as much as possible, the co- solvent will be even more preferably anhydrous ethanol, optionally dried on 3 A sieves.
• the concentration of the co-solvent e.g. ethanol
• the amount of ethanol should not exceed around 40% w/w of the total weight of the formulation.
• it is comprised between 5 and 30%> w/w, preferably between 10 and 20% w/w, even more preferably between 12 and 15% w/w.
• Active ingredients which may be used in the aerosol compositions of the invention are formoterol and stereoisomers, physiologically acceptable salts and solvates thereof.
• Suitable physiological salts include chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, mesilate, ascorbate, salicylate, acetate, succinate, lactate, glutarate or gluconate.
• Said active ingredient can be used alone or in combination with steroids such as beclometasone dipropionate (BDP), flunisolide, mometasone furoate, fluticasone propionate, ciclesonide, budesonide and its 22R-epimer, with anticholinergic atropine-like derivatives such as ipratropium bromide, oxitropium bromide, tiotropium bromide or with drugs useful for the management of respiratory diseases such as methylxanthines, anti-leukotrienes and phosphodiesterase inhibitors.
• steroids such as beclometasone dipropionate (BDP), flunisolide, mometasone furoate, fluticasone propionate, ciclesonide, budesonide and its 22R-epimer
• anticholinergic atropine-like derivatives such as ipratropium bromide, oxitropium bromide, tiotropium bromide or with
• the concentration of formoterol in the HFA formulation will depend on the therapeutic amount to be delivered preferably in one or two actuations.
• drug concentrations are given as (w/v) and as fumarate salt.
• the corresponding percentages as (w/w) can be calculated by determining the density of the vehicle.
• the formulation according to the invention will be filled in a canister fitted with a suitable metering valve.
• a suitable metering valve capable of delivering a volume of between 25 ⁇ l and 100 ⁇ l, e.g. 50 ⁇ l or 63 ⁇ l. 100 ⁇ l is also suitable.
• the concentration of formoterol will vary between 0.003 and 0.192%) w/v, preferably between 0.006 and 0.048% w/v in order to deliver 3 to 48 ⁇ g, preferably 6 or 12 ⁇ g per actuation.
• the final concentration of formoterol fumarate delivered per actuation would be 0.012% w/v; where a 50 ⁇ l metering volume is used, the final concentration of formoterol fumarate would be doubled, e.g. 0.024% w/v and where a 63 ⁇ l metering volume is used, which is the preferred one, the final concentration would be 0.019%> w/v.
• the intended dose regimen is twice or once daily, where the suitable daily dose is in the range of 6 to 48 ⁇ g.
• the apparent pH range is advantageously between 2.5 and 5.0, preferably between 3.0 and 4.5.
• Strong mineral acids preferably selected from hydrochloric, nitric, phosphoric acid can be used to adjust the apparent pH, more preferably hydrochloric acid.
• the amount of acid to be added to reach the desired apparent pH will be pre- determined in the model vehicle reported in EP 1157689 and it will depend on the type and concentration of the active ingredient and the amount of the co-solvent.
• an amount comprised between 3.85 and 4.85 ⁇ l of 1 M HCl is advantageously added, preferably between 4.15 and 4.55 ⁇ l of 1 M HCl, with the optimum of 4.35 ⁇ l.
• the concentration of 1 M HCl is between 0.030%) w/w and 0.045%> w/w, preferably between 0.035% and 0.040% w/w on the total weight of the formulation.
• the amount of water is lower than 1500 ppm, preferably lower than 1000 ppm, even more preferably lower than 500 ppm on the total weight of the formulation.
• the formulations of the invention will be filled into canisters suitable for delivering pharmaceutical aerosol formulations such as plastic or plastic coated glass bottle or preferably a metal can, for example an aluminium can.
• the formulations can also be filled in canisters having part of all of the internal surfaces made of anodised aluminium, stainless steel or lined with an inert organic coating.
• Examples of preferred coatings are epoxy-phenol resins, perfluorinated polymers such as perfluoroalkoxyalkane, perfluoroalkoxyalkylene, perfluoroalkylenes such as poly-tetrafluoroethylene (Teflon), fluorinated- ethylene-propylene, polyether sulfone and a copolymer fluorinated-ethylene- propylene polyether sulfone.
• Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
• cans having a rim with rounded edges preferably a rolled neck or rolled-in rim, a part or full rollover rim can be used according to the teaching of the co-pending application n. WO 02/72448 .
• the canister is closed with a metering valve.
• the metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve.
• the gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene- acrylonitrile rubbers, butyl rubber, neoprene, EPDM (a polymer of ethyl enepropylenediene monomer) and TPE (thermoplastic elastomer).
• EPDM and TPE rubbers are preferred.
• EPDM rubbers are particularly preferred.
• Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (eg. DF10, DF30, DF60), Bespak pic, UK (eg. BK300, BK356, BK357) and 3M-Neotechnic Ltd, UK (eg.
• Valve seals especially the gasket seal, and also the seals around the metering chamber, will preferably be manufactured of a material which is inert to and resists extraction into the contents of the formulation, especially when the contents include ethanol.
• Valve materials especially the material of manufacture of the metering chamber, will preferably be manufactured of a material which is inert to and resists distortion by contents of the formulation, especially when the contents include ethanol.
• Particularly suitable materials for use in manufacture of the metering chamber include polyesters e.g. polybutyleneterephthalate (PBT) and acetals, especially PBT.
• Materials of manufacture of the metering chamber and/or the valve stem may be fluorinated, partially fluorinated or impregnated with fluorine containing substances in order to resist drug deposition.
• a metering valve is crimped onto an aluminum can to form an empty canister.
• the medicament is added to a charge vessel and a mixture of ethanol, optionally water and liquefied propellant is pressure filled through the charge vessel into a manufacturing vessel.
• An aliquot of the formulation is then filled through the metering valve into the canister.
• an aliquot of the liquefied formulation is added to an open canister under conditions which are sufficiently cold that the formulation does not vaporize, and then a metering valve crimped onto the canister.
• an aliquot of medicament dissolved in the solubilising agent is dispensed into an empty canister, a metering valve is crimped on, and then the propellant is filled into the canister through the valve.
• the processes are carried out an in inert atmosphere, for instance by insufflating nitrogen, in order to avoid the uptake of humidity from the air.
• Suitable channeling devices comprise, for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the mouth of a patient e.g. a mouthpiece actuator.
• valve stem is seated in a nozzle block which has an orifice leading to an expansion chamber.
• the expansion chamber has an exit orifice which extends into the mouthpiece.
• Actuator (exit) orifice diameters in the range 0.15 - 0.45 mm especially 0.2 - 0.45 mm are generally suitable e.g. 0.25, 0.30, 0.33 or 0.42 mm. 0.22 mm is also suitable.
• the MDI product may be overwrap in a package, preferably flexible, capable of resisting water ingress. It may also be desired to incorporate a material within the packaging which is able to adsorb any propellant and co- solvent which may leak from the canister, (e.g. a molecular sieve).
• a material within the packaging which is able to adsorb any propellant and co- solvent which may leak from the canister, (e.g. a molecular sieve).
• each tested formulation of the invention can be characterized using a Multistage Cascade Impactor according to the procedure described in European Pharmacopoeia 2 nd edition,
• ACI Andersen Cascade Impactor
• Administration of the formulations of the invention may be indicated for the treatment of mild, moderate or severe, acute or chronic symptoms or for prophylactic treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
• respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
• COPD chronic obstructive pulmonary disease
• Other respiratory disorders characterized by obstruction of the peripheral airways as a result of inflammation and presence of mucus such as chronic obstructive bronchiolitis and chronic bronchitis can also benefit of this kind of formulation.
• a formulation was prepared with the composition as follows:
• the formulation 120 actuations/canister, overage of 40 actuations
• Two actuators were used with orifice diameter of 0.30 and 0.42 mm. Results were obtained as a mean of 2 cans.
• the aerodynamic particle size distribution was determined by ACI, according to the description on page 17 lines 4 to 12.
• the delivery characteristics of the formulation are reported in Table 1 in comparison with the reference CFC formulation currently available on the market (Foradil). In particular the following parameters are reported: i) nominal dose: theoretical dose per single actuation; ii) delivered dose: amount of active particles deposited into the all ACI stages; iii) respirable dose (fine particle dose): amount of active particles of size equal or less than 4.1 microns (S3-AF); iv) respirable fraction (fine particle fraction): ratio between the respirable dose and the delivered dose; v) "superfine” dose: amount of active particles equal or less than 1.1 microns (S6-AF); iv) "superfine” fraction: ratio between the "superfine” dose and the respirable dose.
• the aim of the study was to evaluate the pharmacokinetics of formoterol in 6 healthy volunteers after single administration of the formoterol formulations of Example 1 at 120 ⁇ g dose (10 shots x 12 ⁇ g/shot) in comparison with the marketed CFC formulation (Foradil).
• the experimental protocol is reported as follows:
• the study was a single dose cross-over study; subjects received the drug at 8 a.m.
• the wash-out among different treatments was of at least 1 weeks. Patients were instructed to take 10 doses. Time 0 for each dose was defined as the time when the MDI is first actuated.
• AUCo- 20 m i n is the area under the curve of the plasmatic levels from time 0 h to 20 minutes;
• AUC t is the area under the curve of the plasmatic levels from time 0 h to the last measurable data point.
• the total systemic exposure (see Figure 1), corresponding to the fraction of drug absorbed through the lung plus the amount swallowed and absorbed through the gut, is slightly lower with the formulations of the invention than with the reference one. This may be considered as an advantage since for a drug that exert its activity at the lung level, a reduced systemic exposure may translate in a decreased risk of undesired systemic effects.
• Example 1 filled in standard aluminum cans was stored in different conditions (25°C, 40°C) and for different times (0, 3, 6 months).
• the assay of formoterol was determined by HPLC while the water content was determined by Karl-Fischer method.
• the results, reported in Figure 2 show an inverse linear correlation between the assay of formoterol and the residual amount of water.
• the numbers between brackets refer to time and temperature condition, respectively.
• the formoterol assay for a residual humidity lower than 1500 ppm meets the requirements of the ICH guideline QIA, whereas for a residual humidity higher than 1500 ppm, the assay decreases below 90%.
• the formoterol assay is higher than 95% and therefore meets the requirements of the ICH guideline QIA. Under these storage conditions, the water content maintains below 1000 ppm.
• the storage conditions are the same of that of the reference product Foradil® whereas the shelf life is better, as the latter has to be kept at refrigerator temperature for maximum nine months.

Priority Applications (31)

Applications Claiming Priority (4)

Related Child Applications (3)

Publications (1)

Family

ID=27790093

Family Applications (2)

Family Applications After (1)

Country Status (36)

Cited By (7)

Families Citing this family (37)

Citations (5)

Family Cites Families (58)

• 2003
  • 2003-02-26 JP JP2003572544A patent/JP2005523905A/ja active Pending
  • 2003-02-26 IL IL16384303A patent/IL163843A0/xx unknown
  • 2003-02-26 PT PT03718677T patent/PT1480615E/pt unknown
  • 2003-02-26 US US10/504,151 patent/US20050152846A1/en not_active Abandoned
  • 2003-02-26 PT PT18173392T patent/PT3384931T/pt unknown
  • 2003-02-26 EP EP19166324.4A patent/EP3494995B1/en not_active Expired - Lifetime
  • 2003-02-26 EP EP19171326.2A patent/EP3536344B1/en not_active Expired - Lifetime
  • 2003-02-26 EA EA200401007A patent/EA007735B1/ru not_active IP Right Cessation
  • 2003-02-26 SI SI200331813T patent/SI1480615T1/sl unknown
  • 2003-02-26 PT PT191713262T patent/PT3536344T/pt unknown
  • 2003-02-26 AT AT03718677T patent/ATE465712T1/de active
  • 2003-02-26 HU HUE18173392 patent/HUE044926T2/hu unknown
  • 2003-02-26 SI SI200332611T patent/SI3494995T1/sl unknown
  • 2003-02-26 ME MEP-2008-301A patent/ME00077B/me unknown
  • 2003-02-26 EP EP03718677A patent/EP1480615B1/en not_active Expired - Lifetime
  • 2003-02-26 SI SI200332600T patent/SI3384931T1/sl unknown
  • 2003-02-26 DK DK19166324.4T patent/DK3494995T3/da active
  • 2003-02-26 GE GEAP8391A patent/GEP20063986B/en unknown
  • 2003-02-26 HU HUE19171326A patent/HUE048310T2/hu unknown
  • 2003-02-26 PT PT191663244T patent/PT3494995T/pt unknown
  • 2003-02-26 DK DK18173392.4T patent/DK3384931T3/da active
  • 2003-02-26 NZ NZ535018A patent/NZ535018A/en not_active IP Right Cessation
  • 2003-02-26 BR BRPI0308274A patent/BRPI0308274B8/pt active IP Right Grant
  • 2003-02-26 RS YU76704A patent/RS52387B/en unknown
  • 2003-02-26 HU HUE19166324A patent/HUE049426T2/hu unknown
  • 2003-02-26 ES ES19166324T patent/ES2780127T3/es not_active Expired - Lifetime
  • 2003-02-26 EP EP10156461.5A patent/EP2201964B1/en not_active Expired - Lifetime
  • 2003-02-26 ES ES03718677T patent/ES2342463T3/es not_active Expired - Lifetime
  • 2003-02-26 ES ES18173392T patent/ES2745064T3/es not_active Expired - Lifetime
  • 2003-02-26 LT LTEP19171326.2T patent/LT3536344T/lt unknown
  • 2003-02-26 PL PL372173A patent/PL209212B1/pl unknown
  • 2003-02-26 SI SI200332607T patent/SI3536344T1/sl unknown
  • 2003-02-26 LT LTEP19166324.4T patent/LT3494995T/lt unknown
  • 2003-02-26 ES ES19171326T patent/ES2779273T3/es not_active Expired - Lifetime
  • 2003-02-26 AU AU2003222753A patent/AU2003222753B2/en not_active Expired
  • 2003-02-26 CN CNB038049767A patent/CN100398094C/zh not_active Expired - Lifetime
  • 2003-02-26 DK DK19171326.2T patent/DK3536344T3/da active
  • 2003-02-26 MX MXPA04008372A patent/MXPA04008372A/es active IP Right Grant
  • 2003-02-26 CA CA2477881A patent/CA2477881C/en not_active Expired - Lifetime
  • 2003-02-26 KR KR1020047013491A patent/KR100947409B1/ko active IP Right Grant
  • 2003-02-26 DK DK03718677.2T patent/DK1480615T3/da active
  • 2003-02-26 WO PCT/EP2003/001964 patent/WO2003074024A1/en active Application Filing
  • 2003-02-26 ME MEP-301/08A patent/MEP30108A/xx unknown
  • 2003-02-26 LT LTEP18173392.4T patent/LT3384931T/lt unknown
  • 2003-02-26 DE DE60332321T patent/DE60332321D1/de not_active Expired - Lifetime
  • 2003-02-26 EP EP18173392.4A patent/EP3384931B1/en not_active Expired - Lifetime
  • 2003-02-27 EP EP03743343A patent/EP1480617A2/en not_active Withdrawn
  • 2003-02-27 AU AU2003210370A patent/AU2003210370C1/en not_active Ceased
  • 2003-02-27 MX MXPA04008369A patent/MXPA04008369A/es not_active Application Discontinuation
  • 2003-02-27 CN CNA038049724A patent/CN1638729A/zh active Pending
  • 2003-02-27 WO PCT/EP2003/002004 patent/WO2003074025A2/en active Application Filing
  • 2003-02-27 IL IL16384403A patent/IL163844A0/xx unknown
  • 2003-02-27 GE GEAP8392A patent/GEP20063876B/en unknown
  • 2003-02-27 PL PL03372292A patent/PL372292A1/xx not_active Application Discontinuation
  • 2003-02-27 EA EA200401005A patent/EA008592B1/ru not_active IP Right Cessation
  • 2003-02-27 ME MEP-302/08A patent/MEP30208A/xx unknown
  • 2003-02-27 US US10/505,861 patent/US20050154013A1/en not_active Abandoned
  • 2003-02-27 CA CA2477885A patent/CA2477885C/en not_active Expired - Fee Related
  • 2003-02-27 BR BR0308275-0A patent/BR0308275A/pt not_active IP Right Cessation
  • 2003-02-27 TW TW092104192A patent/TWI347197B/zh not_active IP Right Cessation
  • 2003-02-27 KR KR1020047013502A patent/KR100961603B1/ko not_active IP Right Cessation
  • 2003-02-27 JP JP2003572545A patent/JP2005524664A/ja not_active Withdrawn
  • 2003-02-27 TW TW092104191A patent/TW200303752A/zh unknown
  • 2003-02-27 NZ NZ535017A patent/NZ535017A/en not_active IP Right Cessation
  • 2003-02-27 RS YU76604A patent/RS76604A/sr unknown
  • 2003-02-28 AR ARP030100684A patent/AR038641A1/es not_active Application Discontinuation
  • 2003-02-28 PE PE2003000199A patent/PE20030824A1/es active IP Right Grant
  • 2003-02-28 MY MYPI20030710A patent/MY143517A/en unknown
  • 2003-02-28 AR ARP030100687A patent/AR038644A1/es unknown
  • 2003-02-28 MY MYPI20030711A patent/MY137603A/en unknown
  • 2003-02-28 PE PE2003000202A patent/PE20030827A1/es not_active Application Discontinuation
• 2004
  • 2004-08-06 TN TNP2004000147A patent/TNSN04147A1/en unknown
  • 2004-08-06 TN TNP2004000149A patent/TNSN04149A1/en unknown
  • 2004-08-09 MA MA27817A patent/MA27175A1/fr unknown
  • 2004-08-20 HR HRP20040753 patent/HRP20040753A2/xx not_active Application Discontinuation
  • 2004-08-20 HR HRP20040752AA patent/HRP20040752B1/hr not_active IP Right Cessation
  • 2004-08-27 CO CO04084191A patent/CO5611092A2/es not_active Application Discontinuation
  • 2004-08-27 CO CO04084184A patent/CO5611091A2/es not_active Application Discontinuation
  • 2004-08-31 IL IL163843A patent/IL163843A/en active IP Right Grant
  • 2004-08-31 NO NO20043626A patent/NO342575B1/no not_active IP Right Cessation
  • 2004-08-31 NO NO20043625A patent/NO20043625L/no not_active Application Discontinuation
• 2005
  • 2005-12-12 HK HK05111376.6A patent/HK1079425A1/xx not_active IP Right Cessation
• 2009
  • 2009-06-19 US US12/487,988 patent/US20090263488A1/en not_active Abandoned
• 2010
  • 2010-05-06 JP JP2010106449A patent/JP2010215637A/ja not_active Withdrawn
  • 2010-06-18 CY CY20101100567T patent/CY1111133T1/el unknown
  • 2010-09-01 US US12/873,690 patent/US8313732B2/en not_active Expired - Lifetime
• 2019
  • 2019-09-10 CY CY20191100946T patent/CY1122027T1/el unknown
• 2020
  • 2020-03-16 CY CY20201100230T patent/CY1122875T1/el unknown
  • 2020-03-16 CY CY20201100231T patent/CY1122851T1/el unknown

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events